WallStSmart

Adapthealth Corp (AHCO)vsAstraZeneca PLC (AZN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 1715% more annual revenue ($62.38B vs $3.44B). AZN leads profitability with a 17.7% profit margin vs -11.8%. AZN earns a higher WallStSmart Score of 68/100 (B-).

AHCO

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 3.0Value: 6.7Quality: 4.0
Piotroski: 4/9Altman Z: 0.95

AZN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 8.5Value: 6.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHCOUndervalued (+66.4%)

Margin of Safety

+66.4%

Fair Value

$31.37

Current Price

$7.87

$23.50 discount

UndervaluedFair: $31.37Overvalued
AZNUndervalued (+4.3%)

Margin of Safety

+4.3%

Fair Value

$197.94

Current Price

$185.48

$12.46 discount

UndervaluedFair: $197.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHCO1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

AZN5 strengths · Avg: 8.6/10
Market CapQuality
$293.73B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Free Cash FlowQuality
$3.99B8/10

Generating 4.0B in free cash flow

Areas to Watch

AHCO4 concerns · Avg: 2.8/10
Market CapQuality
$1.00B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

Debt/EquityHealth
1.673/10

Elevated debt levels

Return on EquityProfitability
-33.2%2/10

ROE of -33.2% — below average capital efficiency

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AHCO

The strongest argument for AHCO centers on Price/Book. Revenue growth of 10.9% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bear Case : AHCO

The primary concerns for AHCO are Market Cap, Operating Margin, Debt/Equity. Debt-to-equity of 1.67 is elevated, increasing financial risk.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

AHCO profiles as a turnaround stock while AZN is a mature play — different risk/reward profiles.

AHCO carries more volatility with a beta of 1.32 — expect wider price swings.

AHCO is growing revenue faster at 10.9% — sustainability is the question.

AZN generates stronger free cash flow (4.0B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (68/100 vs 47/100), backed by strong 17.7% margins. AHCO offers better value entry with a 66.4% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adapthealth Corp

HEALTHCARE · MEDICAL DEVICES · USA

AdaptHealth Corp. The company is headquartered in Plymouth Meeting, Pennsylvania.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?